Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma

Journal of Veterinary Medical Science

Rei NAKAHIRA⁴  Masaki MICHISHITA⁴  Takayuki NAKAGAWA³  Tsuyoshi TAJIMA¹  Aya OHTSUKA⁴  Kimimasa TAKAHASHI⁴  Nobuo SASAKI³  Toshiro ARAI² 

[1] Department of Veterinary Pharmacology, Nippon Veterinary and Life Science University, 1�?7�?1 Kyonan-cho, Musashino, Tokyo 180�?8602, Japan;Department of Veterinary Biochemistry, Nippon Veterinary and Life Science University, 1�?7�?1 Kyonan-cho, Musashino, Tokyo 180�?8602, Japan;Department of Veterinary Surgery, The University of Tokyo, 1�?1�?1 Yayoi, Bunkyo, Tokyo 113�?8657, Japan;Department of Veterinary Pathology, Nippon Veterinary and Life Science University, 1�?7�?1 Kyonan-cho, Musashino, Tokyo 180�?8602, Japan

关键词: bevacizumab;    feline mammary carcinoma;    vascular endothelial growth factor (VEGF);    xenograft;   

DOI  :  10.1292/jvms.15-0550

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

References(23)Cited-By(1)Feline mammary carcinomas are characterized by rapid progression and metastases. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis, proliferation and metastasis. The present study aimed to investigate the effects of a single drug therapy of bevacizumab on a xenograft model of feline mammary carcinoma expressing VEGF protein. Bevacizumab treatment suppressed tumor growth by inhibiting angiogenesis and enhancing apoptosis; however, it did not affect the tumor proliferation index. Thus, bevacizumab had anti-tumor effects on a xenograft model, and this may be useful for the treatment of feline mammary carcinoma.

【 授权许可】

Unknown